Company / Accounts Receivable
Apyx Medical Corp Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$16.8M
FY2025
5-year range
$10.6M / $16.8M
FY2021-FY2025
Trend
+8.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has increased for 3 consecutive years, from $11M in FY2022 to $17M in FY2025.
Based on SEC 10-K filings.
$17M in FY2025 with a 5-year CAGR of +14.8%.
Improved from $14M to $17M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +16.5%
- 5-Year CAGR
- +14.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- Apyx Medical Corp's accounts receivable has grown for 3 consecutive years.
- 5-year CAGR of +14.8%, indicating consistent growth.
- In FY2025, accounts receivable increased 8.4% year-over-year.
- Lowest accounts receivable in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -0.02 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $16.8M | +8.4% |
| FY2024 | $15.5M | +10.4% |
| FY2023 | $14.0M | +32.3% |
| FY2022 | $10.6M | -18.7% |
| FY2021 | $13.0M | +55.2% |
| FY2020 | $8.4M | +102.9% |
| FY2019 | $4.1M | -14.8% |
| FY2018 | $4.9M | +0.0% |
| FY2017 | $4.9M | +2.6% |
| FY2016 | $4.7M | +61.8% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026